FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040667783> ?p ?o ?g. }

• W2040667783 endingPage "1457" @default.
• W2040667783 startingPage "1453" @default.
• W2040667783 abstract "No AccessJournal of UrologyAdult Urology1 Oct 2009Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy Antonella Giannantoni, Aroldo Rossi, Ettore Mearini, Michele Del Zingaro, Massimo Porena, and Alfredo Berardelli Antonella GiannantoniAntonella Giannantoni Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author , Aroldo RossiAroldo Rossi Department of Neurology, University of Perugia, Perugia, Italy More articles by this author , Ettore MeariniEttore Mearini Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author , Michele Del ZingaroMichele Del Zingaro Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author , Massimo PorenaMassimo Porena Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author , and Alfredo BerardelliAlfredo Berardelli Department of Neurological Sciences and Neuromed Institute, Sapienza, University of Rome, Rome, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.06.023AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Urinary disturbances are common in patients with Parkinson's disease and multiple system atrophy. We investigated the effectiveness and safety of botulinum toxin type A injected into the detrusor muscle in patients with Parkinson's disease and multiple system atrophy who had refractory overactive bladder symptoms and detrusor overactivity. Materials and Methods: All participants underwent clinical and urodynamic assessment, and completed a quality of life questionnaire before botulinum toxin type A treatment, and 1 and 3 months thereafter. Four patients with Parkinson's disease and 2 with multiple system atrophy were enrolled in the study. All patients received 200 U botulinum toxin type A injected into the detrusor muscle at 20 sites under cystoscopic guidance at a single session on an inpatient basis. Outcome measures were clinical assessment (a voiding diary including daytime and nighttime urinary frequency, and episodes of urgency and urge urinary incontinence), urodynamic assessment (including first volume and maximum pressure of uninhibited detrusor contractions, and maximum cystometric capacity) and pressure flow studies. Results: One and 3 months after botulinum toxin type A injection all patients reported that daytime and nighttime urinary frequency had decreased and quality of life scores improved. No patients had further episodes of urgency and urge urinary incontinence during the 5-month followup. Urodynamics showed improvement in all urinary function variables tested. No systemic side effects were recorded during or after treatment. In all patients post-void urinary residual volume increased and intermittent catheterization was required only in those with multiple system atrophy. Conclusions: The new beneficial effect that we report in a small study sample encourages larger trials to confirm botulinum toxin type A injection into the detrusor muscle as an effective and safe treatment for refractory overactive bladder symptoms and detrusor overactivity related to Parkinson's disease and multiple system atrophy. References 1 : Bladder dysfunction in Parkinsonism: mechanism, prevalence, symptoms and management. Mov Disord2006; 21: 737. Google Scholar 2 : Update of the neurology of Parkinson's disease. Neurourol Urodyn2007; 26: 103. Google Scholar 3 : Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol2001; 165: 491. Link, Google Scholar 4 : Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract2008; 62: 1792. Google Scholar 5 : Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry2004; 7: 951. Google Scholar 6 : Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2008; 70: 1699. Google Scholar 7 : Clinical value of botulinum toxin in neurological indications. Eur J Neurol2006; 13: 20. Google Scholar 8 : Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol2009; 55: 100. Google Scholar 9 : Accuracy of clinical diagnosis of idiopathic Parkinson's disease; clinical pathological study of 100 cases. J Neurol Neurosurg Psychiatry1992; 55: 181. Google Scholar 10 : Second consensus statement on the diagnosis of multiple system atrophy. Neurology2008; 71: 670. Google Scholar 11 : Relation of postvoid residual to urinary tract infection during stroke rehabilitation. Arch Phys Med Rehabil2003; 84: 1369. Google Scholar 12 : Quality of life of persons with urinary incontinence: development of a new measure. Urology1996; 47: 67. Google Scholar 13 : The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures: International Continence Society Standardization Committee. Neurourol Urodyn1999; 18: 139. Google Scholar 14 : Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?: Preliminary results. J Urol2000; 164: 692. Link, Google Scholar 15 : Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol2007; 62: 452. Google Scholar 16 : Neurophysiological effects of botulinum toxin type A. Neurotox Res2006; 9: 109. Google Scholar 17 : Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord2006; 21: 777. Google Scholar 18 : Do the unintended actions of BT at distant sites have clinical implications?. Neurology2009; 72: 1095. Google Scholar 19 : Effects of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol2003; 169: 1896. Link, Google Scholar 20 : Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol2006; 49: 644. Google Scholar 21 : Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol2006; 175: 2341. Link, Google Scholar 22 : Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon2000; 38: 245. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byCrawford E, Hirst K, Kusek J, Donnell R, Kaplan S, McVary K, Mynderse L, Roehrborn C, Smith C and Bruskewitz R (2018) Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical TrialJournal of Urology, VOL. 186, NO. 3, (965-970), Online publication date: 1-Sep-2011.Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, Porena M and Berardelli A (2018) Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive BladderJournal of Urology, VOL. 186, NO. 3, (960-964), Online publication date: 1-Sep-2011. Volume 182Issue 4October 2009Page: 1453-1457 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsParkinson diseaseurinary bladdermultiple system atrophyquality of lifeoveractivebotulinum toxinsAcknowledgmentsDrs. Silvia Proietti and Silvia Giovannozzi assisted with data collection and urodynamics.MetricsAuthor Information Antonella Giannantoni Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author Aroldo Rossi Department of Neurology, University of Perugia, Perugia, Italy More articles by this author Ettore Mearini Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author Michele Del Zingaro Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author Massimo Porena Department of Urology and Andrology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy More articles by this author Alfredo Berardelli Department of Neurological Sciences and Neuromed Institute, Sapienza, University of Rome, Rome, Italy More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2040667783 created "2016-06-24" @default.
• W2040667783 creator A5014528589 @default.
• W2040667783 creator A5027858233 @default.
• W2040667783 creator A5030657607 @default.
• W2040667783 creator A5030704569 @default.
• W2040667783 creator A5046927127 @default.
• W2040667783 creator A5049243723 @default.
• W2040667783 date "2009-10-01" @default.
• W2040667783 modified "2023-09-25" @default.
• W2040667783 title "Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy" @default.
• W2040667783 cites W1578634963 @default.
• W2040667783 cites W1965836027 @default.
• W2040667783 cites W1973849826 @default.
• W2040667783 cites W2002063178 @default.
• W2040667783 cites W2008541313 @default.
• W2040667783 cites W2008560062 @default.
• W2040667783 cites W2015046581 @default.
• W2040667783 cites W2018299323 @default.
• W2040667783 cites W2023584252 @default.
• W2040667783 cites W2051448097 @default.
• W2040667783 cites W2051693254 @default.
• W2040667783 cites W2062168648 @default.
• W2040667783 cites W2064865346 @default.
• W2040667783 cites W2068710144 @default.
• W2040667783 cites W2074646478 @default.
• W2040667783 cites W2090660395 @default.
• W2040667783 cites W2129974957 @default.
• W2040667783 cites W2130736332 @default.
• W2040667783 cites W2137847719 @default.
• W2040667783 cites W2155299862 @default.
• W2040667783 cites W2159270533 @default.
• W2040667783 cites W2795831496 @default.
• W2040667783 doi "https://doi.org/10.1016/j.juro.2009.06.023" @default.
• W2040667783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19683298" @default.
• W2040667783 hasPublicationYear "2009" @default.
• W2040667783 type Work @default.
• W2040667783 sameAs 2040667783 @default.
• W2040667783 citedByCount "105" @default.
• W2040667783 countsByYear W20406677832012 @default.
• W2040667783 countsByYear W20406677832013 @default.
• W2040667783 countsByYear W20406677832014 @default.
• W2040667783 countsByYear W20406677832015 @default.
• W2040667783 countsByYear W20406677832016 @default.
• W2040667783 countsByYear W20406677832017 @default.
• W2040667783 countsByYear W20406677832018 @default.
• W2040667783 countsByYear W20406677832019 @default.
• W2040667783 countsByYear W20406677832020 @default.
• W2040667783 countsByYear W20406677832021 @default.
• W2040667783 countsByYear W20406677832022 @default.
• W2040667783 countsByYear W20406677832023 @default.
• W2040667783 crossrefType "journal-article" @default.
• W2040667783 hasAuthorship W2040667783A5014528589 @default.
• W2040667783 hasAuthorship W2040667783A5027858233 @default.
• W2040667783 hasAuthorship W2040667783A5030657607 @default.
• W2040667783 hasAuthorship W2040667783A5030704569 @default.
• W2040667783 hasAuthorship W2040667783A5046927127 @default.
• W2040667783 hasAuthorship W2040667783A5049243723 @default.
• W2040667783 hasConcept C126322002 @default.
• W2040667783 hasConcept C126894567 @default.
• W2040667783 hasConcept C141071460 @default.
• W2040667783 hasConcept C142724271 @default.
• W2040667783 hasConcept C204787440 @default.
• W2040667783 hasConcept C2777478456 @default.
• W2040667783 hasConcept C2778941218 @default.
• W2040667783 hasConcept C2779134260 @default.
• W2040667783 hasConcept C2779734285 @default.
• W2040667783 hasConcept C2779762690 @default.
• W2040667783 hasConcept C2780616540 @default.
• W2040667783 hasConcept C2781172350 @default.
• W2040667783 hasConcept C71924100 @default.
• W2040667783 hasConceptScore W2040667783C126322002 @default.
• W2040667783 hasConceptScore W2040667783C126894567 @default.
• W2040667783 hasConceptScore W2040667783C141071460 @default.
• W2040667783 hasConceptScore W2040667783C142724271 @default.
• W2040667783 hasConceptScore W2040667783C204787440 @default.
• W2040667783 hasConceptScore W2040667783C2777478456 @default.
• W2040667783 hasConceptScore W2040667783C2778941218 @default.
• W2040667783 hasConceptScore W2040667783C2779134260 @default.
• W2040667783 hasConceptScore W2040667783C2779734285 @default.
• W2040667783 hasConceptScore W2040667783C2779762690 @default.
• W2040667783 hasConceptScore W2040667783C2780616540 @default.
• W2040667783 hasConceptScore W2040667783C2781172350 @default.
• W2040667783 hasConceptScore W2040667783C71924100 @default.
• W2040667783 hasIssue "4" @default.
• W2040667783 hasLocation W20406677831 @default.
• W2040667783 hasLocation W20406677832 @default.
• W2040667783 hasOpenAccess W2040667783 @default.
• W2040667783 hasPrimaryLocation W20406677831 @default.
• W2040667783 hasRelatedWork W1969146667 @default.
• W2040667783 hasRelatedWork W2075738478 @default.
• W2040667783 hasRelatedWork W2283448968 @default.
• W2040667783 hasRelatedWork W2597402884 @default.
• W2040667783 hasRelatedWork W2767918166 @default.
• W2040667783 hasRelatedWork W3025416379 @default.
• W2040667783 hasRelatedWork W4247443105 @default.
• W2040667783 hasRelatedWork W4256631357 @default.
• W2040667783 hasRelatedWork W69721835 @default.

• next